A Florida woman has filed suit against the manufacturers of the Zantac after developing cancer. The Boynton Beach Zantac lawsuit alleges that the manufacturers deliberately allowed an unsafe product to remain on the market.
According to the Boynton Beach Zantac lawsuit claim, 44-year-old Jill Goldstein was diagnosed with a hormone receptor-positive ductal carcinoma in Aug. 2019. The following month, Goldstein underwent a lumpectomy, removing the tumor and part of her breast. Goldstein alleges that her regular consumption of Zantac increased her risk of developing cancer by 240%.
Using a 2008 study by the Fred Hutchinson Cancer Research Center as evidence, Jill Goldstein filed against the manufacturers of Zantac:
- Sanofi U.S.
- Boehringer Ingelheim Pharmaceuticals
The lawsuit alleges the manufacturers are guilty of selling products with design defects, not warning consumers, negligence, breaching an express warranty, breaching an implied warranty, and negligent misrepresentation.
The 2008 study Goldstein’s suit references states that consuming ranitidine regularly increases the risk of ductal carcinoma by 2.2 and increases risks of hormone receptor-positive ductal carcinoma by 2.4-fold compared to those with no ranitidine exposure. The study does stipulate that further studies would need to confirm this and could offer no explanation for why ranitidine appeared to increase the risks of cancer.
Officials representing Sanofi U.S. have refuted the claims of the Boynton Beach Zantac lawsuit and assured consumers that the company was “working closely with the FDA and other regulatory bodies to evaluate any potential safety risks associated with ranitidine products.”
By James Parker
James Parker is a content writer from Coral Springs, Florida. He majored in Communication and Media Studies at Stetson University, where he spent much of his time bringing the cutting edge of medical research to his peers’ attention. When he’s not writing, he enjoys rewatching “Almost Famous” or curling up with a good book.